MAR | Acarix decides on a guaranteed rights issue of approximately SEK 56 million

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent
approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a
maximum of 86,156,738 shares with preferential rights for the Company's existing shareholders
(the "Rights Issue"). If fully subscribed, the Rights Issue will provide the Company with
approximately SEK 56 million before deduction of costs related to the Rights Issue.
The Company has received guarantee undertakings from external investors of approximately SEK 50.4 million,corresponding to approximately 90 percent of the Rights Issue. The amount from SEK 50.4 million
up to approximately SEK 56 million in the Rights Issue is thus not covered by guarantee
undertakings. The board of directors will today announce through a separate press release a notice
to attend the Extraordinary General Meeting, which will be held on 11 August 2020, to approve the
board of director's decision on the Rights Issue.

PR_Acarix_Guaranteed Rights Issue

PR_Acarix_Garanterad Företrädesemission


About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit